Catalyst Wire Dossier Catalyst Wire Dossier

Tolododekin Alfa

ANK-101 · Ankyra Therapeutics, Inc
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Tolododekin Alfa, covering 2025-08-03 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors [Phase 1]

See pricing